These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26386588)

  • 1. Rituximab treatment for refractory steroid-resistant nephrotic syndrome.
    Kamei K; Ishikura K
    Pediatr Nephrol; 2016 Feb; 31(2):337-8. PubMed ID: 26386588
    [No Abstract]   [Full Text] [Related]  

  • 2. Commonality of rituximab pharmacokinetic disposition in nephrotic syndrome and autoimmune cytopenias in chronic lymphocytic leukemia patients.
    Srinivas NR
    Pediatr Nephrol; 2016 Feb; 31(2):335-6. PubMed ID: 26260383
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome.
    Counsilman CE; Jol-van der Zijde CM; Stevens J; Cransberg K; Bredius RG; Sukhai RN
    Pediatr Nephrol; 2015 Aug; 30(8):1367-70. PubMed ID: 26054711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for childhood refractory nephrotic syndrome.
    Iijima K
    Pediatr Int; 2011 Oct; 53(5):617-621. PubMed ID: 21771179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotic syndrome: Efficacy of rituximab in challenging nephrotic syndrome.
    Lemley KV; Mak RH
    Nat Rev Nephrol; 2015 May; 11(5):257-8. PubMed ID: 25752834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis.
    Zhao Z; Liao G; Li Y; Zhou S; Zou H
    Sci Rep; 2015 Feb; 5():8219. PubMed ID: 25645999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in steroid-dependent nephrotic syndrome.
    El Koumi M
    Iran J Kidney Dis; 2013 Nov; 7(6):502-6. PubMed ID: 24241100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in patients with the steroid-resistant nephrotic syndrome.
    Bagga A; Sinha A; Moudgil A
    N Engl J Med; 2007 Jun; 356(26):2751-2. PubMed ID: 17596616
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
    Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
    Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab efficiency in children with steroid-dependent nephrotic syndrome.
    Sellier-Leclerc AL; Macher MA; Loirat C; Guérin V; Watier H; Peuchmaur M; Baudouin V; Deschênes G
    Pediatr Nephrol; 2010 Jun; 25(6):1109-15. PubMed ID: 20238230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Rituximab in Children With Steroid- and Cyclosporine-resistant and Steroid- and Cyclosporine-dependent Nephrotic Syndrome.
    Hoseini R; Sabzian K; Otukesh H; Zafaranloo N; Panahi P; Rahimzadeh N; Nakhaie S; Akhavan Sepehi M
    Iran J Kidney Dis; 2018 Jan; 12(1):27-32. PubMed ID: 29421774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
    Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
    Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome.
    Miyabe Y; Takei T; Iwabuchi Y; Moriyama T; Nitta K
    Clin Exp Nephrol; 2016 Feb; 20(1):103-10. PubMed ID: 26138356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
    Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
    Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
    Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
    Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mild form of rituximab-associated lung injury in two adolescents treated for nephrotic syndrome.
    Spatafora M; Bellini T; Giordano C; Ghiggeri GM
    BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26661285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.
    Colucci M; Carsetti R; Cascioli S; Casiraghi F; Perna A; Ravà L; Ruggiero B; Emma F; Vivarelli M
    J Am Soc Nephrol; 2016 Jun; 27(6):1811-22. PubMed ID: 26567244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with rituximab of immunotactoid glomerulopathy exhibiting nephrotic syndrome
.
    Karasawa K; Uchida K; Nakano T; Moriyama T; Nitta K
    Clin Nephrol; 2018 Sep; 90(3):222-226. PubMed ID: 30049299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.
    Grenda R; Jarmużek W; Rubik J; Piątosa B; Prokurat S
    Eur J Pediatr; 2016 Sep; 175(9):1133-1137. PubMed ID: 27364906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.